Literature DB >> 12128277

Myasthenia gravis in pregnancy: report on 69 cases.

Josip Djelmis1, Marija Sostarko, Davor Mayer, Marina Ivanisevic.   

Abstract

OBJECTIVE: To review our experience with pregnancies in women with myasthenia gravis (MG). STUDY
DESIGN: Sixty nine pregnancies among 65 women with MG patients managed by our department over 28 years were included. The course of the disease in pregnancy, mode of delivery and postpartal period were evaluated.
RESULTS: One pregnancy miscarried. In 15% of patients the MG deteriorated in pregnancy a further 16% in the puerperium. 17% of pregnancies were delivered by cesarean section, one due to myasthenia exacerbation. All women with puerperal infections developed exacerbations. One neonatal death, not attributable to myasthenia, was recorded. Transitory neonatal myasthenia gravis (TNMG) was diagnosed in 30% infants. Its incidence was inversely associated with maternal disease duration (P < 0.05). Newborns of thymectomized mothers showed lower rate of neonatal myasthenia compared to those of non-thymectomized women (P < 0.05).
CONCLUSIONS: MG patients can have normal pregnancy and delivery but the course is unpredictable. Shorter disease history and infection predispose to puerperal exacerbation. Maternal thymectomy lessens the likelihood of neonatal myasthenia. An interdisciplinary approach is required for managing the pregnant women with MG.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12128277     DOI: 10.1016/s0301-2115(02)00051-9

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  27 in total

Review 1.  [Course and treatment of myasthenia gravis during pregnancy].

Authors:  J Klehmet; J Dudenhausen; A Meisel
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

2.  Intercommunication between the neuroendocrine and immune systems: focus on myasthenia gravis.

Authors:  Jacqueline Mays; Cherié L Butts
Journal:  Neuroimmunomodulation       Date:  2011-09-22       Impact factor: 2.492

3.  Anti-MuSK-positive myasthenia gravis diagnosed during pregnancy: new challenges for an old disease?

Authors:  Ana Raquel Neves; Pitorra Monteiro; Anabela Matos; Isabel Santos Silva
Journal:  BMJ Case Rep       Date:  2015-01-05

4.  Increased risk for clinical onset of myasthenia gravis during the postpartum period.

Authors:  Marion I Boldingh; Angelina H Maniaol; Cathrine Brunborg; Harald Weedon-Fekjær; Jan J G M Verschuuren; Chantal M E Tallaksen
Journal:  Neurology       Date:  2016-10-21       Impact factor: 9.910

5.  Myasthenia gravis and pregnancy: retrospective evaluation of 27 pregnancies in a tertiary center and comparison with previous studies.

Authors:  Atakan Tanacan; Erdem Fadiloglu; Gonca Ozten; Ali Can Gunes; Gokcen Orgul; Mehmet Sinan Beksac
Journal:  Ir J Med Sci       Date:  2019-05-09       Impact factor: 1.568

Review 6.  Myasthaenia Gravis: Clinical management issues before, during and after pregnancy.

Authors:  Ali Hassan; Zakia M Yasawy
Journal:  Sultan Qaboos Univ Med J       Date:  2017-10-10

Review 7.  Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes.

Authors:  Charlotte Vrinten; Angeli M van der Zwaag; Stephanie S Weinreich; Rob J P M Scholten; Jan J G M Verschuuren
Journal:  Cochrane Database Syst Rev       Date:  2014-12-17

8.  Myasthenia gravis during pregnancy.

Authors:  Shahnaz Akhtar Chaudhry; Biruthvie Vignarajah; Gideon Koren
Journal:  Can Fam Physician       Date:  2012-12       Impact factor: 3.275

Review 9.  Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations.

Authors:  Yang Mao-Draayer; Sandra Thiel; Elizabeth A Mills; Tanuja Chitnis; Michelle Fabian; Ilana Katz Sand; M Isabel Leite; Sven Jarius; Kerstin Hellwig
Journal:  Nat Rev Neurol       Date:  2020-02-20       Impact factor: 42.937

Review 10.  The immune system's role in the biology of autism.

Authors:  Paula Goines; Judy Van de Water
Journal:  Curr Opin Neurol       Date:  2010-04       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.